For many years, topical minoxidil solutions and foams have been widely used to treat hair loss and support hair regrowth. More recently, low-dose oral minoxidil (LDOM) has gained increasing attention as an alternative option for men and women experiencing pattern hair loss.
Originally developed as an oral medication for severe hypertension, minoxidil was later found to stimulate hair growth as a side effect. This discovery eventually led to the development of the topical formulations commonly used today. While topical minoxidil remains effective for many individuals, some patients may struggle with issues such as scalp irritation, greasy residue, inconvenience with daily application or limited results.
Low-dose oral minoxidil offers a different approach by delivering the medication systemically through the bloodstream rather than through direct scalp application. As an off-label treatment, it has increasingly become an important option for patients seeking a more convenient and potentially effective way to slow hair loss and improve hair density.
Minoxidil is a medication that is widely recognised for its topical forms, such as solutions and foams used to treat hair loss. In recent years, dermatologists have increasingly prescribed low-dose oral minoxidil (LDOM) as an alternative treatment for androgenetic alopecia and other forms of hair thinning.
Originally developed as an oral medication for high blood pressure, minoxidil is now used in much smaller “micro-doses” for hair loss treatment. Standard doses for hypertension typically range from 10 to 40 mg daily, whereas low-dose oral minoxidil for hair loss is usually prescribed in significantly lower doses to stimulate hair follicles while reducing the risk of systemic cardiovascular side effects. (Jimenez-Cauhe et al., 2025).
One of the main limitations of topical minoxidil is that it must first be converted into its active form, minoxidil sulfate, by an enzyme called sulfotransferase (SULT1A1) within the hair follicles. However, not everyone has sufficient levels of this enzyme in the scalp. Studies suggest that a significant proportion of patients may have low sulfotransferase activity, which can reduce their response to topical minoxidil treatment. (Dias FR et al., 2025).
Low-dose oral minoxidil bypasses this limitation. When taken orally, the medication is metabolised in the liver through a different sulfotransferase enzyme pathway, allowing more consistent systemic delivery of the active drug to hair follicles (Dias FR et al., 2025). This is one reason why oral minoxidil has gained increasing attention among patients who struggle with topical treatments or experience limited results.
Low-dose oral minoxidil works through several mechanisms that help stimulate hair growth and support healthier hair follicles. Although its exact mechanism is still not fully understood, research has identified several important pathways involved in its effects on the scalp and hair cycle.
Minoxidil opens ATP-sensitive potassium channels, causing the smooth muscle cells within blood vessel walls to relax. This vasodilation increases blood flow to the scalp, helping deliver more oxygen and nutrients to hair follicles that may be weakened or miniaturised by hair loss (Gupta et al., 2023).
Minoxidil also affects the natural hair cycle by shortening the telogen, or resting phase, while prolonging the anagen or active growth phase. This allows hair follicles to remain in the growth stage for longer periods, contributing to the development of thicker, longer terminal hairs over time (Patel, 2023).
Studies suggest that minoxidil may stimulate the release of vascular endothelial growth factor (VEGF), which activates the Wnt/β-catenin signalling pathway. This pathway plays an important role in hair follicle development, regeneration, and ongoing hair growth (Gupta et al., 2023).
Both oral and topical minoxidil are commonly used to treat hair loss, but they differ in how they are administered, processed by the body, and tolerated by patients. A 2024 meta-analysis comparing the two formulations found that oral minoxidil is non-inferior to topical minoxidil in improving hair density and hair diameter (Sobral et al., 2024).
For many patients, however, the decision between oral and topical minoxidil often comes down to convenience, treatment response, and side effect profile.
Topical minoxidil requires regular application to the scalp, often once or twice daily. Some patients find long-term use difficult due to greasy residue, scalp irritation, disruption to hairstyling routines, or the inconvenience of daily application. These factors can affect treatment adherence over time (Sobral et al., 2024).
Low-dose oral minoxidil offers a simpler alternative for some individuals, as it is taken as a daily pill rather than applied directly to the scalp.
Topical minoxidil depends on scalp sulfotransferase enzymes to convert the medication into its active form. Patients with low enzyme activity may experience limited improvement with topical treatment.
Because oral minoxidil is metabolised through the liver instead, it bypasses this scalp enzyme limitation and may be more effective for certain individuals who previously saw little or no response from topical formulations.
One important difference between the two formulations is the risk of hypertrichosis, or unwanted hair growth on other parts of the body. Studies show that hypertrichosis occurs more frequently with oral minoxidil compared to topical minoxidil because the medication is delivered systemically through the bloodstream (Sobral et al., 2024).
Because low-dose oral minoxidil (LDOM) is an off-label treatment for hair loss, dosing must be individualised and carefully monitored by a physician. Before starting treatment, baseline assessments such as blood pressure and weight checks are commonly recommended to ensure patient safety (Gupta AK et al., 2026).
Current consensus recommendations for androgenetic alopecia generally follow these dosage ranges:
| Patient Profile | Recommended Starting Dose | Maximum Daily Dose |
| Men (MPHL) | 1.25 mg to 2.5 mg per day | 5 mg per day |
| Women (FPHL) | 0.625 mg to 1.25 mg per day | 2.5 mg per day |
Clinical Note: Hair regrowth with oral minoxidil takes time, and results are not immediate. Noticeable improvement typically requires at least 4 to 6 months of consistent treatment (Gupta AK et al., 2026).
Low-dose oral minoxidil (LDOM) is generally well tolerated when prescribed and monitored appropriately. However, because it is a systemic medication, patients should still be aware of its potential side effects and how they are typically managed.
Some patients experience a temporary increase in hair shedding during the first few weeks of treatment. Studies suggest this may occur in approximately 16% to 32% of patients, usually beginning around 2 to 4 weeks after starting treatment (Jimenez-Cauhe et al., 2025).
This occurs because minoxidil shifts resting hairs out of the telogen phase to allow newer anagen hairs to grow. Although the shedding phase can feel alarming, it is often temporary and may indicate that the medication is actively affecting the hair cycle.
Hypertrichosis, or unwanted hair growth on other parts of the body, is one of the most commonly reported side effects of oral minoxidil, particularly among women. Excess hair growth may occur on areas such as the forehead, temples, cheeks, forearms, or legs.
Despite this, many patients continue treatment because of the improvement in scalp hair growth. A 2026 study found that 93.2% of women experiencing hypertrichosis did not consider it significant enough to discontinue treatment (Sharma E et al., 2026).
Because minoxidil was originally developed as a blood pressure medication, low-dose oral minoxidil may occasionally cause cardiovascular side effects such as lightheadedness, dizziness, or mild tachycardia (increased heart rate). These effects are generally uncommon and have been reported in approximately 1% to 4% of patients (Jimenez-Cauhe et al., 2025).
Some patients may experience fluid retention, which can appear as swelling in the lower legs (oedema) or puffiness around the eyes (periorbital oedema). In many cases, these symptoms can be managed through dose adjustment, reducing sodium intake, or additional medications when appropriate (Jimenez-Cauhe et al., 2025).
Low-dose oral minoxidil may be considered for men and women experiencing pattern hair loss, particularly when hair thinning continues to progress or topical treatments have not worked well. It is increasingly used in patients looking for a more convenient alternative to topical minoxidil or those who struggle with daily scalp application.
Oral minoxidil may be suitable for:
Because oral minoxidil is a systemic medication, suitability should always be assessed by a doctor. Factors such as blood pressure, cardiovascular history, pregnancy status, existing medications and overall health should be reviewed before starting treatment.
Hair regrowth with low-dose oral minoxidil takes time, and results are usually gradual rather than immediate. Because hair follicles follow slow natural growth cycles, most patients require several months of consistent treatment before noticeable improvement becomes visible.
The treatment journey often progresses in stages:
Some patients may notice increased hair shedding within the first 2 to 8 weeks of treatment. This phase, commonly referred to as the “dread shed,” occurs because resting hairs are pushed out to make way for newer hairs entering the active growth phase.
Although this temporary shedding can feel concerning, it is usually short-lived and may indicate that the medication is actively affecting the hair cycle.
By around 3 to 4 months, some patients may begin noticing early changes such as:
The extent of early improvement varies between individuals.
More noticeable improvements in scalp coverage, hair thickness, and hair density typically become clearer after 6 to 12 months of regular treatment. Patients with earlier-stage hair loss often respond more favourably than those with long-standing or advanced hair thinning.
Results with oral minoxidil usually require ongoing treatment to maintain hair growth. If the medication is stopped, the hair growth cycle gradually returns to its previous state, and hair shedding may slowly recur over time.
Treatment outcomes can also be influenced by factors such as the severity and duration of hair loss, underlying medical conditions, consistency with treatment and whether oral minoxidil is combined with other hair restoration therapies.
Low-dose oral minoxidil has emerged as an increasingly popular treatment option for men and women experiencing hair loss, particularly androgenetic alopecia. By delivering the medication systemically through the bloodstream, it offers an alternative for patients who struggle with topical formulations due to scalp irritation, inconvenience or limited treatment response. Research suggests that oral minoxidil may help improve hair density, prolong the hair growth phase and support healthier hair follicles over time when used consistently under medical supervision.
Like all medical treatments, oral minoxidil is not suitable for everyone and should be carefully prescribed based on an individual’s medical history, hair loss pattern and treatment goals. Although results typically take several months to become visible, many patients experience gradual improvements in hair thickness, density and overall scalp coverage with ongoing use.
If you are experiencing persistent hair thinning or pattern hair loss and would like to explore whether oral minoxidil may be suitable for you, schedule a consultation with APAX Medical & Aesthetic Clinic for a personalised hair loss assessment and treatment plan.
Both oral and topical minoxidil can be effective for hair loss treatment. However, some patients respond better to oral minoxidil because it bypasses the scalp enzyme limitations required for topical activation. Many patients also find it easier to remain consistent with a once-daily pill compared to regular topical application.
Oral minoxidil is FDA-approved for the treatment of severe high blood pressure at much higher doses. Its use for hair loss is considered an off-label treatment, which is a common medical practice in dermatology. For hair loss, doctors prescribe significantly lower doses to support hair growth while reducing the risk of systemic side effects.
The “dread shed” refers to a temporary increase in hair shedding that may occur during the first few weeks of treatment. This happens because older resting hairs are pushed out to allow newer hairs to enter the active growth phase. Although it can feel concerning, this shedding is usually temporary and may indicate that the medication is actively affecting the hair cycle.
Because oral minoxidil works systemically through the bloodstream, it may stimulate hair growth in areas beyond the scalp. Some patients notice slightly increased hair growth on the face, arms, legs, or body, a condition known as hypertrichosis. This side effect is generally more common in women and is often manageable with routine hair removal methods.
Since minoxidil was originally developed as a blood pressure medication, low-dose oral minoxidil may occasionally cause side effects such as lightheadedness, dizziness, fluid retention or mild heart palpitations. These effects are generally uncommon at low doses but should still be monitored under medical supervision. Patients experiencing severe swelling, chest pain or fainting should seek medical attention promptly.
Hair growth is a gradual biological process, so results with oral minoxidil are not immediate. Some patients may experience temporary shedding during the first 1 to 2 months, followed by early improvement around 3 to 4 months. More noticeable changes in hair density and scalp coverage often become clearer after 6 to 12 months of consistent treatment.
Oral minoxidil may not be suitable for everyone. It is generally avoided in pregnant or breastfeeding women, individuals with significant heart conditions, uncontrolled blood pressure or patients taking multiple blood pressure medications without specialist supervision. A proper medical assessment is important before starting treatment.
Like most non-surgical hair loss treatments, oral minoxidil works as a maintenance treatment rather than a permanent cure. Continued use is usually required to maintain hair growth results. If treatment is stopped, hair shedding may gradually return over the following months as the hair cycle reverts to its previous state.
Dr. Moses Ng is a distinguished professional in the field of aesthetic medicine, renowned for his expertise in advanced cosmetic procedures. With over 15 years of experience, extensive training and a keen eye for detail, Dr. Ng specializes in a wide range of treatments, including injectables, laser therapies, and acne scar management.
Dr. Moses Ng’s commitment to excellence and patient-centric approach have earned him a reputation as a trusted clinician in aesthetic medicine. His continuous pursuit of the latest advancements in the field ensures that his patients receive the highest standard of care and the most effective treatments available.
